FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, manufacturing controls, lot release assays, and monitoring.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Sorbye on Separating NET G3 From NEC Before Choosing Therapy
2
Dr Lewis on Cabozantinib and Time Toxicity in Neuroendocrine Tumors
3
Oncolytic Virus SVV-001 Plus Ipi/Nivo Is Safe in High-Grade Neuroendocrine Cancers
4
FDA Sets April 2027 Decision Date for Rivoceranib Combo in HCC
5